Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03549078
Recruitment Status : Recruiting
First Posted : June 7, 2018
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
This intervention is designed to promote enhanced use of compensation strategies including calendar and task list use, and organization systems, as well as increased engagement with brain health activities including physical exercise, cognitive activities, and stress reduction.

Condition or disease Intervention/treatment Phase
Functional Aging Subjective Cognitive Concerns Compensation Strategies Brain Health Activities Behavioral: Intervention Not Applicable

Detailed Description:
The purpose of this study is to test the feasibility and efficacy of a 10-week multi-dimensional intervention for older adults with subjective cognitive concerns (SCC). The goal of this intervention is to enhance compensation skills related to everyday executive and everyday memory functions through training in the systematic use of a calendar system, goal setting and task list system, and organizational strategies within the context of the individual's daily life. This multidimensional intervention program also targets engagement in healthy lifestyle activities (physical exercise, intellectual stimulation, positive emotional functioning) to further promote brain health and functional resilience. Importantly, both treatment components work synergistically as the use of compensation strategies assists in building healthy activities into daily routines (e.g., scheduling exercise into one's calendar and putting it on a task list).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Randomized Evaluation of a Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia
Actual Study Start Date : January 1, 2017
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Arm Intervention/treatment
Experimental: Intervention
Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
Behavioral: Intervention

Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).

Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity.





Primary Outcome Measures :
  1. Everyday Compensation Questionnaire [ Time Frame: Change from baseline to immediately post-intervention and through 6 month follow up ]
    a 54-item self-report questionnaire that asks participants how often they engage in a variety of activities that help them stay cognitively and physically active.

  2. Everyday Cognition [ Time Frame: Change from baseline to immediately post-intervention and through 6 month follow up ]
    self-rated questionnaire of cognitively-based everyday abilities. The ECog comprises of 39 items on which the participant's current level of everyday functioning is compared to 10 years earlier. Items are rated on a four-point scale: 1= better or no change compared to 10 years earlier; 4= consistently much worse. Higher scores indicate greater functional limitations


Secondary Outcome Measures :
  1. Beck Depression Inventory [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    Measures depressive symptomatology

  2. Beck Anxiety Inventory [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    Measures anxiety symptomatology

  3. List learning task [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    measures learning and memory

  4. Executive function task [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    measures executive function

  5. psychomotor speed task [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    measures psychomotor speed function

  6. GRIT [ Time Frame: Measured at baseline, immediately after intervention, and 3 and 6 month follow up visits ]
    an 8-item questionnaire assessing consistency of interest and perseverance of effort on a five-point scale: 1 = not at all like me, 5 = very much like me.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A positive complaint in response to two questions ('Do you feel like your memory or other aspects of thinking are becoming worse?'; 'Does this worry you?')
  • normal cognitive performance corrected for age and education on a global measure of cognitive functioning
  • independent in all activities of daily living.
  • English speaking;
  • Available informant to complete surveys;
  • Ambulatory

Exclusion Criteria:

  • Known neurological condition;
  • Severe psychiatric illness (e.g., current depression).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549078


Contacts
Layout table for location contacts
Contact: Katherine G Denny, Ph.D. 916-734-4301 kgdenny@ucdavis.edu
Contact: Sarah Farias, PhD 916-734-6442 farias@ucdavis.edu

Locations
Layout table for location information
United States, California
University of California Davis Recruiting
Sacramento, California, United States, 95816
Contact: Katherine G Denny, Ph.D.    916-734-4301    kgdenny@ucdavis.edu   
Sponsors and Collaborators
University of California, Davis
Investigators
Layout table for investigator information
Principal Investigator: Katherine G Denny, PhD University of California, Davis

Publications:
Layout table for additonal information
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT03549078     History of Changes
Other Study ID Numbers: 967764
First Posted: June 7, 2018    Key Record Dates
Last Update Posted: June 12, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Tauopathies
Neurodegenerative Diseases